Literature DB >> 27151603

The risk of community-acquired pneumonia among 9803 patients with coeliac disease compared to the general population: a cohort study.

F Zingone1,2, A Abdul Sultan1, C J Crooks1, L J Tata1, C Ciacci2, J West1.   

Abstract

BACKGROUND: Patients with coeliac disease are considered as individuals for whom pneumococcal vaccination is advocated. AIM: To quantify the risk of community-acquired pneumonia among patients with coeliac disease, assessing whether vaccination against streptococcal pneumonia modified this risk.
METHODS: We identified all patients with coeliac disease within the Clinical Practice Research Datalink linked with English Hospital Episodes Statistics between April 1997 and March 2011 and up to 10 controls per patient with coeliac disease frequency matched in 10-year age bands. Absolute rates of community-acquired pneumonia were calculated for patients with coeliac disease compared to controls stratified by vaccination status and time of diagnosis using Cox regression in terms of adjusted hazard ratios (HR).
RESULTS: Among 9803 patients with coeliac disease and 101 755 controls, respectively, there were 179 and 1864 first community-acquired pneumonia events. Overall absolute rate of pneumonia was similar in patients with coeliac disease and controls: 3.42 and 3.12 per 1000 person-years respectively (HR 1.07, 95% CI 0.91-1.24). However, we found a 28% increased risk of pneumonia in coeliac disease unvaccinated subjects compared to unvaccinated controls (HR 1.28, 95% CI 1.02-1.60). This increased risk was limited to those younger than 65, was highest around the time of diagnosis and was maintained for more than 5 years after diagnosis. Only 26.6% underwent vaccination after their coeliac disease diagnosis.
CONCLUSIONS: Unvaccinated patients with coeliac disease under the age of 65 have an excess risk of community-acquired pneumonia that was not found in vaccinated patients with coeliac disease. As only a minority of patients with coeliac disease are being vaccinated there is a missed opportunity to intervene to protect these patients from pneumonia.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2016        PMID: 27151603     DOI: 10.1111/apt.13652

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  11 in total

1.  Splenic volume differentiates complicated and non-complicated celiac disease.

Authors:  Tom van Gils; Petula Nijeboer; Jan Hein Tm van Waesberghe; Veerle Mh Coupé; Kiki Janssen; Jessy A Zegers; Shaikh A Nurmohamed; Georg Kraal; Sabine Ci Jiskoot; Gerd Bouma; Chris Jj Mulder
Journal:  United European Gastroenterol J       Date:  2016-08-17       Impact factor: 4.623

2.  Association Between Celiac Disease and Mortality Risk in a Swedish Population.

Authors:  Benjamin Lebwohl; Peter H R Green; Jonas Söderling; Bjorn Roelstraete; Jonas F Ludvigsson
Journal:  JAMA       Date:  2020-04-07       Impact factor: 56.272

3.  Celiac Disease Presenting in a Community-Based Gastroenterology Practice: Obesity and Bone Disease Are Common.

Authors:  Giovanni A Roldan; Sehrish Jamot; Krzysztof Kopec; Amber Charoen; Daniel Leffler; Edward R Feller; Samir A Shah
Journal:  Dig Dis Sci       Date:  2022-06-01       Impact factor: 3.199

4.  Mucosal healing and the risk of serious infections in patients with celiac disease.

Authors:  Louise Emilsson; Benjamin Lebwohl; Peter Hr Green; Joseph A Murray; Karl Mårild; Jonas F Ludvigsson
Journal:  United European Gastroenterol J       Date:  2017-04-24       Impact factor: 4.623

5.  Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults.

Authors:  Jan Zirk-Sadowski; Jane A Masoli; Joao Delgado; Willie Hamilton; W David Strain; William Henley; David Melzer; Alessandro Ble
Journal:  J Am Geriatr Soc       Date:  2018-04-20       Impact factor: 5.562

6.  Outcome measures in coeliac disease trials: the Tampere recommendations.

Authors:  Jonas F Ludvigsson; Carolina Ciacci; Peter Hr Green; Katri Kaukinen; Ilma R Korponay-Szabo; Kalle Kurppa; Joseph A Murray; Knut Erik Aslaksen Lundin; Markku J Maki; Alina Popp; Norelle R Reilly; Alfonso Rodriguez-Herrera; David S Sanders; Detlef Schuppan; Sarah Sleet; Juha Taavela; Kristin Voorhees; Marjorie M Walker; Daniel A Leffler
Journal:  Gut       Date:  2018-02-13       Impact factor: 23.059

Review 7.  Community-Acquired Bacterial Pneumonia-Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin.

Authors:  Roopali Sharma; Christian E Sandrock; Joni Meehan; Nicolette Theriault
Journal:  Clin Drug Investig       Date:  2020-10       Impact factor: 2.859

Review 8.  Immune response to vaccines in children with celiac disease.

Authors:  Caterina Anania; Francesca Olivero; Alessandra Spagnolo; Claudio Chiesa; Lucia Pacifico
Journal:  World J Gastroenterol       Date:  2017-05-14       Impact factor: 5.742

9.  Risk of COVID-19 in celiac disease patients.

Authors:  Fabiana Zingone; Anna D'Odorico; Greta Lorenzon; Ilaria Marsilio; Fabio Farinati; Edoardo Vincenzo Savarino
Journal:  Autoimmun Rev       Date:  2020-08-13       Impact factor: 9.754

10.  The use of an invitational letter to increase the vaccine uptake of patients with coeliac disease.

Authors:  Joseph Moneim; Hera Asad; Eman Butt; Jamil Shah Foridi; Yasmin Khan; Safwaan Patel; Jawad Qureshi; Ravi Thakar
Journal:  Prim Health Care Res Dev       Date:  2019-10-30       Impact factor: 1.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.